Summary
For Year 2026-27, Venmax Drugs And Pharmaceuticals reports the following shareholding: Total Promoters at 15.14%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0%, and Retail at 84.86%. This breakdown provides a quick snapshot of ownership distribution for Venmax Drugs And Pharmaceuticals in 2026-27.
Venmax Drugs And Pharmaceuticals FAQs
As of 04-2026, the promoter shareholding in Venmax Drugs And Pharmaceuticals stands at 15.14% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Venmax Drugs And Pharmaceuticals is 0% and 0% respectively.
The retail shareholding of the Venmax Drugs And Pharmaceuticals is 84.86%.
Changes in shareholding patterns of Venmax Drugs And Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Venmax Drugs And Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Venmax Drugs And Pharmaceuticals Associated Pages
- Venmax Drugs And Pharmaceuticals Share Price
- Venmax Drugs And Pharmaceuticals Share Price chart
- Venmax Drugs And Pharmaceuticals Fundamental Analysis
- Venmax Drugs And Pharmaceuticals Technical Analysis
- Venmax Drugs And Pharmaceuticals Peer Comparison
- Venmax Drugs And Pharmaceuticals Share Price History
- Venmax Drugs And Pharmaceuticals Board of Directors
